Background-Prior studies in heart failure (HF) have used the Modification of Diet in Renal Disease (MDRD) 
I
t is well recognized that renal dysfunction is common in patients with heart failure (HF) and is an adverse prognostic factor. [1] [2] [3] [4] [5] [6] [7] [8] Although prior studies examining the prevalence and prognostic import of renal dysfunction in HF have used the Modification of Diet in Renal Disease (MDRD) equation to calculate the estimated glomerular filtration rate (eGFR), 9 recent studies comparing MDRDgenerated eGFRs against radionuclide gold standards have demonstrated that the MDRD systematically underestimates true eGFR, particularly in patients with an eGFR Ͼ60 mL/min. 10 Thus, studies using the MDRD equation to calculate eGFR may overestimate the prevalence of renal dysfunction in study participants. 11 In clinical practice, patients misclassified as having renal dysfunction may be exposed to potential harms because such patients often are treated with lower doses of drugs, and diagnostic tests using contrast media are avoided.
in 8254 patients a new equation for calculating the eGFR, which is more accurate than the MDRD when compared against the radionuclide gold standard. 12 However, few patients in the CKD-EPI validation studies had HF, and the true prevalence and prognostic import of renal dysfunction in HF if the CKD-EPI equation is used rather than the MDRD equation is uncertain. In addition, it is unknown whether renal dysfunction prevalence and prognostic importance differs between patients with HF with reduced ejection fraction (HF-REF) and those with HF with preserved ejection fraction (HF-PEF). In particular, there is debate about whether risk truly increases at eGFR Ͻ60 mL/min or whether lower eGFR levels might be a more appropriate cut point to identify at-risk individuals because most patients with HF are elderly and eGFR declines with age. 11 We designed the present study to examine the frequency of renal dysfunction in patients with HF using the CKD-EPI and the MDRD formulas. We also examined the association between renal dysfunction and mortality in patients with HF-REF and HF-PEF.
Methods
The methods, including details about study selection criteria and the flow of included studies, and main results of the MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) metaanalysis have been described in full elsewhere. 13 For this analysis, we pooled individual patient data from the 25 studies in the MAGGIC meta-analysis (2 pharmacotherapy randomized controlled trials, 4 management strategy randomized controlled trials, and 19 observational studies) that included data on serum creatinine (SCr) levels and collected all-cause mortality outcomes prospectively in patients with HF and did not restrict their study entry criteria by left ventricular ejection fraction. The meta-analysis protocol was approved by The University of Auckland Human Subjects Ethics Committee. Data (demographics, comorbidities, therapy, symptom status, clinical variables, laboratory variables, and outcomes) from the individual studies were recoded into a uniform format at the Central Coordinating Centre at The University of Auckland and incorporated into 1 database.
For this analysis, HF-PEF was prespecified as a baseline left ventricular ejection fraction of Ն50%, and we defined renal dysfunction as an eGFR of Ͻ60 mL/min, which corresponds to National Kidney Foundation KDOQI (Kidney Disease Outcomes Quality Initiative) stage 3 and 4 kidney disease. 14 Covariates were all defined at baseline, including anemia (hemoglobin Ͻ120 g/L in women and Ͻ130 g/L in men). We calculated eGFR by 2 methods. For the MDRD equation, none of the studies used isotope dilution to measure SCr, and thus, we used 186ϫ(SCr) Data are presented as meanϮSD, %, or median (interquartile range). eGFR indicates estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration Group; HF-PEF, heart failure with preserved ejection fraction; HF-REF, heart failure with reduced ejection fraction; MI, myocardial infarction; AF, atrial fibrillation; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction.
indicates the minimum of SCr/k or 1, and max indicates the maximum of SCr/k or 1.
Data are presented as meanϮSD, unless otherwise indicated. Tests for linear trend were constructed from orthogonal contrasts for continuous variables, and the Cochran-Armitage trend test was used for ordered categorical data. CIs around person time rates were calculated using Miettinen exact test (www.openepi.com [accessed September 19, 2011] ). Areas under the receiver operating characteristic curve were compared using the ROCCONTRAST option of the logistic regression procedure of the SAS software program. The Cox proportional hazard of time to all-cause death within 3 years from the baseline study visit was used to model the hazard of varying degrees of renal dysfunction (strata generated using the MDRD and the CKD-EPI formulas separately), adjusted for age, sex, ischemic etiology, anemia, hypertension, diabetes, and atrial fibrillation and stratified by study. The variables chosen for the model were selected for clinical relevance; data were available for these variables in Ͼ94% of the patients in this analysis. Models were constructed from those individuals with complete data for each model. No imputation of missing data was used. Unless otherwise stated, the procedures of SAS version 9.2 statistical software were used for all analyses. All tests were 2 tailed, and PϽ0.05 was considered significant.
Results
In 20 754 patients with HF (15 962 with HF-REF; 4792 with HF-PEF; mean age, 68 years; men, 66%), all-cause mortality was 24% over a median follow-up of 2 years (deaths per 1000 patient-years, 150.5; 95% CI, 146.3-154.7). There were 136.7 (95% CI, 128.2-145.7) deaths per 1000 patient-years in those with HF-PEF and 154.1 (95% CI, 149.4 -158.9) in those with HF-REF.
Patients with HF-REF were more likely to be men and to have ischemic etiology and diabetes mellitus (comparisons done using 2 tests) ( Table 1 ). The distribution of eGFR was similar in patients with HF-PEF and HF-REF (Figure 1) . Patients with lower eGFRs exhibited worse HF symptom status, higher comorbidity burden, and lower use of cardiovascular medications (all PϽ0.001) ( Table 1) .
Using the MDRD equation, 10 589 (51%) patients had an eGFR Ͻ60 mL/min (meeting the National Kidney Foundation KDOQI definition of stage 3 or 4 kidney disease); using the CKD-EPI equation, 11 422 (55%) patients had an eGFR Ͻ60 mL/min (Figure 1) . However, using the CKD-EPI formula resulted in 3760 (18%) patients being reclassified between KDOQI categories (Figure 2, Table 2 ), with reclassification occurring across all categories of eGFR. Eighteen percent (nϭ671) of those reclassified were placed in a higher eGFR category with the CKD-EPI than with the MDRD equation (ie, they were reclassified to a lower risk group); the remaining 3089 (82%) were placed in a lower eGFR category with the CKD-EPI than with the MDRD equation (ie, they were reclassified to a higher risk group). Although the CKD-EPI and MDRD equations demonstrated similar discrimination in predicting all-cause mortality in patients with HF, the CKD-EPI-derived eGFR performed statistically significantly better than the model using MDRD (Table 3) , and review of the misclassification matrix (Table 2) confirmed that the all-cause mortality rates in the reclassified patients more closely reflected their CKD-EPI-based risk categorization than their MDRD-based risk stratification (net reclassification improvement, 3.7%; 95% CI, 1.5%-5.9%).
Although the adjusted Cox proportional hazard ratio for the association between renal dysfunction and mortality in patients with HF-REF increased sequentially as eGFR declined to Ͻ60 mL/min ( Figure 3A) , the association was less evident in HF-PEF, where there were fewer patients and lower event rates in each category (Pϭ0.048 for interaction between ejection fraction groups) ( Figure 3B ). Indeed, perusal of the adjusted hazard ratios in Figure 3A and 3B reveals that renal dysfunction was a stronger predictor of all-cause mortality in patients with HF-REF than in those with HF-PEF. Of note, the hazard ratios were adjusted for age; sex; etiology; and presence or absence of anemia, atrial fibrillation, hypertension, or diabetes and were stratified by study, and the adjusted hazard ratios were almost identical when baseline medication use was included in the models (data not shown). The association between gradients of CKD-EPI-defined eGFR and mortality was similar irrespective of age ( Figure 4) .
Discussion
This large meta-analysis based on individual patient data from Ͼ20 000 individuals confirms previous reports of greater symptom burden, reduced likelihood of being prescribed evidence-based therapies, and poorer adjusted survival in patients with renal dysfunction and HF. 7, 15 An important novel finding is that the use of the CKD-EPI equation to calculate the eGFR rather than use of the MDRD equation increases the apparent prevalence of renal dysfunction in both patients with HF-PEF and patients with HF-REF. This finding is contrary to prior studies conducted in healthier and younger patient populations, which suggested higher prevalence of renal dysfunction using the MDRD equation compared to the CKD-EPI equation. 9 -12,16 -18 However, the present data are consistent with a recent report from the Nijmegen Biomedical Study, which found that the CKD-EPI formula provided lower values of eGFR than the MDRD formula in older subjects. 19 Thus, impaired renal function is even more common in HF than previously appreciated. Indeed, the present study may even have underestimated the prevalence of renal dysfunction because we did not have data on albuminuria, cystatin C, or rate of decline in eGFR, all of which are indicators of renal dysfunction that may not be apparent in patients with eGFR still in the normal range. 20 -23 Although the KEEP (Kidney Early Evaluation Program) investigators reported that only 30% of the 2455 patients with HF in their cohort had a CKD-EPI eGFR Ͻ60 mL/min, 18 the diagnosis of HF in KEEP was based on self-report, and the cohort was substantially younger than the present cohort.
A second important observation from the current analysis is that eGFR is a stronger predictor of all-cause mortality in HF-REF than in HF-PEF, and for any given eGFR category, mortality is higher in patients with HF-REF than in patients with HF-PEF. The stronger relationship between mortality and eGFR in HF-REF emphasizes the relevance of the cardiorenal syndrome to prognosis in these patients. Indeed, it is likely that reduction in eGFR is a marker for reduced cardiac output, which is a more-important prognostic factor in patients with HF-REF than in those with HF-PEF. Further, competing mortality risks from comorbid conditions, such as cancer and chronic obstructive lung disease, are likely to play a larger role in prognosis in HF-PEF. 24 Although the present study reports on a large, wellcategorized, and heterogeneous cohort of patients with HF who are similar to other population-based HF cohorts, 25 there are some limitations. First, we only have renal function and covariate data at baseline. Use of a single baseline SCr level to calculate each patient's eGFR (by either the MDRD or the CKD-EPI equation) may overestimate the prevalence of kidney disease. 11, 26 However, this would have introduced a null bias into the study, leading to an underestimation of the magnitude of the association between renal dysfunction and outcomes, and the QICKD (Quality Improvement in Chronic Kidney Disease) study recently reported that using 2 eGFR measurements at least 3 months apart rather than just a single measurement only reduced the prevalence estimates for CKD by Ϸ1%. 27 Second, we do not have any data on unmeasured covariates, such as body mass index and levels of brain natriuretic peptide, parathyroid hormone, C-reactive protein, or cholesterol; studies comparing these levels in patients with and without renal dysfunction and the effects of interventions on these levels and subsequent clinical outcomes clearly are needed. However, we did adjust for anemia in the multivariable analyses and showed in a cohort of 754 patients followed at a specialized HF clinic (in whom we had hemoglobin data) that renal insufficiency is an independent prognostic factor, even after adjusting for hemoglobin values. 7 In the same vein, we do not have data on other renal function metrics, such as albuminuria, 22 rate of change in eGFR, 28 or cystatin C levels, 21, 29 which appear to be prognostically important in patients regardless of eGFR level; however, this mimics clinical practice in that the majority of patients with HF are managed without access to cystatin C levels. Finally, we acknowledge that there is variability between laboratories in measurement of SCr levels before the introduction of isotope-dilution mass spectrometry standardization in the mid-2000s; however, this variability was shown to predominantly introduce error at higher eGFR levels (ie, Ͼ60 mL/min), which were not the focus of the present study.
In conclusion, despite the limitations, the study demonstrates that reduced renal function is even more common than previously appreciated in HF, regardless of ejection fraction. We also confirm that reduced eGFR is a stronger predictor of death in patients with HF-REF than in those with HF-PEF. Finally, mirroring the findings from the KEEP in subjects at high risk of kidney disease, 18 we demonstrate that in patients with HF, use of the CKD-EPI formula to calculate eGFR appears to offer better mortality risk stratification than the MDRD formula.
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CLINICAL PERSPECTIVE
Compared to the radionuclide gold standard for the assessment of renal function, the Chronic Kidney Disease-Epidemiology Collaboration Group equation more accurately calculates estimated glomerular filtration rate than the Modification of Diet in Renal Disease equation. In an analysis of 20 754 patients (15 962 with heart failure with reduced ejection fraction and 4792 with heart failure with preserved ejection fraction), we found that using the Chronic Kidney Disease-Epidemiology Collaboration Group equation rather than the Modification of Diet in Renal Disease equation results in higher estimates of renal dysfunction (55% versus 51%) and better mortality risk stratification. Regardless of which equation was used, reduced estimated glomerular filtration rate was a stronger predictor of all-cause mortality in patients with heart failure with reduced ejection fraction than those with heart failure with preserved ejection fraction.
